Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
This article was originally published in The Pink Sheet Daily
The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.
You may also be interested in...
Ambrx China Head Feng Tian On Building Biobetters And Partnerships In China: An Interview With PharmAsia News
Ambrx China head Feng Tian talks about the company’s China strategy and his experiences in making deals with local companies.
Versatile next-generation antibody-drug conjugate platforms promise to turn out ADCs with better specificity and safety than current technologies, as well as combination therapeutics like bi-specific antibodies, but old-school molecules continue to move through clinical trials and gain approval.
Unlike most work in antibody-drug conjugates, however, the collaboration will not focus on oncology but on a broad array of undisclosed targets that may be applicable in a wide variety of indications.